Long-term adherence to interferon beta therapy in relapsing-remitting multiple sclerosis - PubMed (original) (raw)
Clinical Trial
doi: 10.1159/000111875. Epub 2007 Nov 30.
Affiliations
- PMID: 18057899
- DOI: 10.1159/000111875
Clinical Trial
Long-term adherence to interferon beta therapy in relapsing-remitting multiple sclerosis
E Portaccio et al. Eur Neurol. 2008.
Abstract
Background/aims: To assess the proportion and the reasons of drop-outs in relapsing-remitting multiple sclerosis patients treated with interferon-beta (IFNB) and the outcome of switching subjects.
Methods: Patients stopping IFNB were classified according to the reason of drop-out: perceived lack of efficacy (PLE) side effects (SE) and other reasons. Long-term adherence was described using the Kaplan-Meier curves.
Results: We evaluated 225 subjects (158 women; age = 36.6 +/- 9.2 years, disease duration = 8.0 +/- 6.1 years, Expanded Disability Status Scale score = 1.9 +/- 1.2) who received Betaferon (46), Avonex (88) and Rebif (91) therapy. The mean follow-up duration was 4.2 +/- 2.7 years. Forty-six percent of patients suspended therapy, 29% because of PLE, 15% because of SE and the remaining 2% due to other reasons. Twenty-five out of 33 subjects who suspended IFNB because of SE and 62 out of 65 patients who suspended the therapy due to PLE were switched to another disease-modifying drug. At the end of the follow-up, the majority of these patients could continue the treatment.
Conclusions: When starting IFNB therapy in relapsing-remitting multiple sclerosis, a relatively high proportion of discontinuation is to be expected over time. Switching from a treatment to another taking into account the reasons of drop-out and the disease activity is a suitable option.
Copyright 2007 S. Karger AG, Basel.
Similar articles
- Comparison of Betaferon, Avonex, and Rebif in treatment of relapsing-remitting multiple sclerosis.
Etemadifar M, Janghorbani M, Shaygannejad V. Etemadifar M, et al. Acta Neurol Scand. 2006 May;113(5):283-7. doi: 10.1111/j.1600-0404.2006.00585.x. Acta Neurol Scand. 2006. PMID: 16629762 Clinical Trial. - Non-adherence to interferon-beta therapy in Swedish patients with multiple sclerosis.
Cunningham A, Gottberg K, von Koch L, Hillert J. Cunningham A, et al. Acta Neurol Scand. 2010 Mar;121(3):154-60. doi: 10.1111/j.1600-0404.2009.01285.x. Epub 2010 Jan 6. Acta Neurol Scand. 2010. PMID: 20055771 - Switching first-line disease-modifying therapy after failure: impact on the course of relapsing-remitting multiple sclerosis.
Gajofatto A, Bacchetti P, Grimes B, High A, Waubant E. Gajofatto A, et al. Mult Scler. 2009 Jan;15(1):50-8. doi: 10.1177/1352458508096687. Epub 2008 Oct 15. Mult Scler. 2009. PMID: 18922831 Clinical Trial. - Clinical characteristics of responders to interferon therapy for relapsing MS.
Waubant E, Vukusic S, Gignoux L, Dubief FD, Achiti I, Blanc S, Renoux C, Confavreux C. Waubant E, et al. Neurology. 2003 Jul 22;61(2):184-9. doi: 10.1212/01.wnl.0000078888.07196.0b. Neurology. 2003. PMID: 12874396 Review. - The challenges of measuring disability accumulation in relapsing-remitting multiple sclerosis: evidence from interferon beta treatments.
Kieseier BC. Kieseier BC. Expert Rev Neurother. 2014 Jan;14(1):105-20. doi: 10.1586/14737175.2014.869478. Expert Rev Neurother. 2014. PMID: 24417500 Review.
Cited by
- The Adherence and Outcomes Benefits of Using a Connected, Reusable Auto-Injector for Self-Injecting Biologics: A Narrative Review.
Antalfy A, Berman K, Everitt C, Alten R, Latymer M, Godfrey CM. Antalfy A, et al. Adv Ther. 2023 Nov;40(11):4758-4776. doi: 10.1007/s12325-023-02671-2. Epub 2023 Sep 21. Adv Ther. 2023. PMID: 37733212 Free PMC article. Review. - Reasons to switch: a noninterventional study evaluating immunotherapy switches in a large German multicentre cohort of patients with relapsing-remitting multiple sclerosis.
Mäurer M, Tiel-Wilck K, Oehm E, Richter N, Springer M, Oschmann P, Manzel A, Hieke-Schulz S, Zingler V, Kandenwein JA, Ziemssen T, Linker RA. Mäurer M, et al. Ther Adv Neurol Disord. 2019 Dec 19;12:1756286419892077. doi: 10.1177/1756286419892077. eCollection 2019. Ther Adv Neurol Disord. 2019. PMID: 31903096 Free PMC article. - Emerging oral immunomodulating agents - focus on teriflunomide for the treatment of multiple sclerosis.
Nwankwo E, Allington DR, Rivey MP. Nwankwo E, et al. Degener Neurol Neuromuscul Dis. 2012 Mar 10;2:15-28. doi: 10.2147/DNND.S29022. eCollection 2012. Degener Neurol Neuromuscul Dis. 2012. PMID: 30890875 Free PMC article. Review. - Patient satisfaction and healthcare services in specialized multiple sclerosis centres in Germany.
Becker V, Heeschen V, Schuh K, Schieb H, Ziemssen T. Becker V, et al. Ther Adv Neurol Disord. 2018 Jan 23;11:1756285617748845. doi: 10.1177/1756285617748845. eCollection 2018. Ther Adv Neurol Disord. 2018. PMID: 29399052 Free PMC article. - Persistence to disease-modifying therapies for multiple sclerosis in a Canadian cohort.
Melesse DY, Marrie RA, Blanchard JF, Yu BN, Evans C. Melesse DY, et al. Patient Prefer Adherence. 2017 Jun 28;11:1093-1101. doi: 10.2147/PPA.S138263. eCollection 2017. Patient Prefer Adherence. 2017. PMID: 28721023 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources